Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
Company Details
Lyell Immunopharma Questions
Lyell Immunopharma's helpline number is 1 650-695-0677
Lyell Immunopharma's website is lyell.com
Lyell Immunopharma's LinkedIn profile is https://www.linkedin.com/company/lyell
Lyell Immunopharma has
253 employees.
View email and phone details for 253
employees at Lyell Immunopharma.
Lyell Immunopharma's industry is
Biotechnology Research
Lyell Immunopharma's top competitors are
Shape Therapeutics Inc.,
Kyverna Therapeutics,
Arsenal Biosciences, Inc.,
Outpace Bio,
Allogene Therapeutics,
Umoja Biopharma,
Sonoma Biotherapeutics, Inc.,
Sana Biotechnology, Inc.,
Tune Therapeutics,
Immpact Bio.
Lyell Immunopharma's categories are Biotechnology Research
